Abstract
Background Identifying factors that protect against macular pucker (MP) is crucial for developing effective treatments. We hypothesize that soluble vascular endothelial growth factor receptor 2 (sVEGFR2), a decoy receptor for VEGF signaling, may provide such protection.
Methods We performed a genome-wide association (GWAS) meta-analysis on three independent studies of sVEGFR2 protein quantitative trait loci (pQTL), which was used to identify novel variants and select variants strongly associated with sVEGFR2 levels. We investigated the association between sVEGFR2 levels and the risk of MP using cis-Mendelian Randomization (cis-MR) and Bayesian colocalization. We also used the UKB-PPP study of sVEGFR2 pQTL, which used a different method for measuring plasma protein, to validate the results from cis-MR and colocalization.
Results GWAS meta-analysis identified four novel variants associated with sVEGFR2 levels, rs9411335 (MED27), rs6992534 (ERI1), rs11893824 (LIMS2), and rs7678559 (PCDH7). Cis-MR analysis suggested that higher levels of sVEGFR2, genetically predicted using the meta-analysis dataset, were associated with a lower risk of MP (OR 0.86, 95% CI 0.77-0.95, P = 4.6 × 10−3). Colocalization supported shared genetic variants in the VEGFR2 gene region between sVEGFR2 and MP (PPH4 = 0.92). Using sVEGFR2 pQTL from UKB-PPP study, sVEGFR2’s inverse association with MP was validated by cis-MR (OR 0.86, 95% CI 0.78-0.96, P = 4.4 × 10−3) and colocalization (PPH4 = 0.95). Sensitivity analyses showed no evidence of pleiotropy or reverse causality, though some heterogeneity was found.
Conclusions Our study suggested that sVEGFR2 has a protective effect against MP and could be a potential therapeutic target. Further research is necessary to elucidate its protective mechanisms and validate its translational implications.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding source was applied to this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All GWAS data are publicly available.
List of abbreviations
- MP
- macular pucker
- sVEGFR2
- soluble vascular endothelial growth factor receptor 2
- mVEGFR2
- membrane-bound VEGFR2
- GWAS
- genome-wide association studies
- pQTL
- protein quantitative trait loci
- MR
- mendelian randomization
- IVW
- inverse variance weighted
- MED27
- mediator complex subunit 27
- ERI1
- exoribonuclease 1
- LIMS2
- LIM zinc finger domain containing 2
- PCDH7
- protocadherin 7
- UKB-PPP
- UK Biobank Pharma Proteomics Project
- CADD
- combined annotation-dependent depletion
